<PAGE>   1
                                                                   EXHIBIT 10.2




                                                                    CONFIDENTIAL


CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTION.

                             JOINT VENTURE AGREEMENT

                                      AMONG

                         GRELAN PHARMACEUTICAL CO., LTD.

                                       AND

                        BIONUMERIK PHARMACEUTICALS, INC.






                                 AUGUST 30, 2000


<PAGE>   2





                                TABLE OF CONTENTS
<TABLE>
<S>                                                                                                              <C>
Recitals..........................................................................................................1

1.   Definitions..................................................................................................2
     1.1       BNP7787 Products...................................................................................2
     1.2       Karenitecin Products...............................................................................2
     1.3       Mercedes Products..................................................................................2
     1.4       PDE4 Products......................................................................................2
     1.5       COX-2 Products.....................................................................................3
     1.6       Venture Products BN................................................................................3
     1.7       Venture Products GR................................................................................3
     1.8       Venture Products...................................................................................3
     1.9       BioNumerik Improvements............................................................................3
     1.10      Grelan Improvements................................................................................3
     1.11      Improvements.......................................................................................3
     1.12      BioNumerik Patent Rights...........................................................................4
     1.13      Grelan Patent Rights...............................................................................4
     1.14      Patent Rights......................................................................................4
     1.15      Patents............................................................................................4
     1.16      Know-How...........................................................................................4
     1.17      Affiliate(s).......................................................................................4
     1.18      Confidential Information...........................................................................5
     1.19      Effective Date.....................................................................................5
     1.20      Government Regulatory Approvals....................................................................5
     1.21      IND Submission.....................................................................................5
     1.22      New Drug Application Approval or NDA Approval......................................................5
     1.23      Steering Committee.................................................................................5
     1.24      Stock Purchase Agreement...........................................................................6
     1.25      Sublicensee........................................................................................6
     1.26      Territory..........................................................................................6
     1.27      Trademarks.........................................................................................6

2.   LICENSE GRANTS BY BIONUMERIK.................................................................................6
     2.1       Research and Development Grant.....................................................................6
     2.2       Grant to Market, Sell and Distribute...............................................................6

3.   LICENSE GRANTS AND TRANSFER BY GRELAN........................................................................7
     3.1       Research and Development Grant.....................................................................7
     3.2       Grant to Market, Sell and Distribute...............................................................7
     3.3       Transfer Regarding Rights Under Existing BNP7787 Agreement.........................................7

4.   SUBLICENSES AND OTHER DISTRIBUTION METHODS FOR VENTURE PRODUCTS..............................................8
     4.1       Distribution Methods and Branch Office.............................................................8
     4.2       Identification of Sublicensees.....................................................................8
     4.3       Right to Grant Sublicenses.........................................................................8
     4.4       Division of Sublicensing Fees and Other Payments...................................................9
     4.5       Third Party Offers or Statements of Interest.......................................................9
</TABLE>




                                       i
<PAGE>   3

<TABLE>
<S>                                                                                                                <C>
5.   RIGHTS OF FIRST REFUSAL FOR VENTURE PRODUCTS BN AND DEVELOPMENT RIGHTS.......................................9
     5.1       Right of First Refusal.............................................................................9
     5.2       Development Rights................................................................................10
     5.3       Development Outside Territory.....................................................................10

6.   INFORMATION SHARING AND DEVELOPMENT COSTS...................................................................11
     6.1       Pre-Clinical Studies..............................................................................11
     6.2       Government Approvals and Clinical Trials..........................................................11
     6.3       Copies and Provision of Information...............................................................13
     6.4       Supplies of Product for Pre-Clinical Studies and Clinical Trials..................................14
     6.5       Provision of Know-How.............................................................................14

7.   MANUFACTURING RIGHTS FOR VENTURE PRODUCTS AND
     PURCHASE OF APPROVED PRODUCTS BY THE VENTURE................................................................15
     7.1       Manufacturing Rights for Venture Products BN......................................................15
     7.2       Manufacturing Rights for Venture Products GR......................................................16
     7.3       Distribution and Sale of Venture Products.........................................................17
     7.4       Commercial Supply Arrangements ...................................................................17
     7.5       Product Labeling..................................................................................18

8.   STEERING COMMITTEE .........................................................................................18
     8.1       Formation and Composition.........................................................................18
     8.2       Duties............................................................................................18
     8.3       Meetings..........................................................................................18
     8.4       Recommendation Regarding Management...............................................................18
     8.5       Identification of Consultants.....................................................................19

9.   DEVELOPMENT AND COMMERCIALIZATION PLAN......................................................................19
     9.1       General Diligence Efforts.........................................................................19
     9.2       Target Development and Commercialization Plan.....................................................19

10.  PATENT MATTERS..............................................................................................19
     10.1      BioNumerik Patent Maintenance ....................................................................19
     10.2      GRELAN Patent Maintenance and Assistance .........................................................20
     10.3      No Present Notification of Infringement-BioNumerik ...............................................20
     10.4      No Present Notification of Infringement-Grelan ...................................................21
     10.5      Enforcement of Patents and Proprietary Rights ....................................................21

11. IMPROVEMENTS.................................................................................................22
     11.1      BioNumerik Improvements Included..................................................................22
     11.2      Grelan Improvements Included......................................................................23
     11.3      Joint Improvements................................................................................23
     11.4      Sublicense of Improvements........................................................................23

12.  TRADEMARKS AND TRADEMARK RIGHT..............................................................................24
     12.1      ..................................................................................................24
     12.2      ..................................................................................................24
     12.3      ..................................................................................................24
</TABLE>




                                       ii
<PAGE>   4

<TABLE>
<S>                                                                                                            <C>
13.  CONFIDENTIALITY.............................................................................................24
     13.1      Confidential and Proprietary Information..........................................................24
     13.2      Matters Not Included as Confidential Information..................................................25
     13.3      Survival of Confidentiality.......................................................................26

14.  PROVISION FOR VENTURE FUNDING...............................................................................26

15.  ACCOUNTING..................................................................................................26

16.  USE OF NAMES................................................................................................27

17.  INDEMNIFICATION.............................................................................................28
     17.1      BioNumerik Indemnification........................................................................28
     17.2      Grelan Indemnification............................................................................28
     17.3      KI Pharma Indemnification ........................................................................28

18.  DURATION AND TERMINATION OF AGREEMENT.......................................................................29
     18.1     Duration...........................................................................................29
     18.2     Termination........................................................................................29
     18.3     Effect of Expiration or Termination................................................................30

19.  BIONUMERIK REPRESENTATIONS & WARRANTIES.....................................................................32
     19.1      Due Organization and Authority....................................................................32
     19.2      Safety of Product(s)..............................................................................32
     19.3      No Pending Action Against BioNumerik..............................................................32

20.  Grelan Representations and Warranties.......................................................................33
     20.1      Due Organization and Authority....................................................................33
     20.2      Safety of Product(s)..............................................................................33
     20.3      No Pending Action Against Grelan..................................................................33

21.  ASSIGNMENTS.................................................................................................33
     21.1      Assignment Restrictions...........................................................................33
     21.2      Sale of Business..................................................................................34
     21.3      Assignment to Affiliates..........................................................................34

22.  MISCELLANEOUS...............................................................................................34
     22.1      Regulatory Communications.........................................................................34
     22.2      Adverse Events....................................................................................35
     22.3      Liability Insurance...............................................................................35
     22.4      Litigation........................................................................................35
     22.5      Auditors..........................................................................................35
     22.6      Marketing Analysis and Reports....................................................................35
     22.7      Notice / Reports..................................................................................36
     22.8      Severability......................................................................................36
     22.9      Counterparts......................................................................................36
     22.10     Warranty Disclaimer...............................................................................37
     22.11     Force Majeure.....................................................................................37
     22.12     Arbitration.......................................................................................37
</TABLE>


                                      iii

<PAGE>   5

<TABLE>
<S>                                                                                                           <C>
     22.13     Export Controls...................................................................................38
     22.14     Construction / Jurisdiction / Official Language...................................................38

23.  ENTIRE AGREEMENT............................................................................................38

24.  CAPTIONS....................................................................................................39

SIGNATURES.......................................................................................................39

ATTACHMENT A-1...................................................................................................40
ATTACHMENT A-2...................................................................................................41
ATTACHMENT A-3...................................................................................................42
ATTACHMENT A-4...................................................................................................43
ATTACHMENT A-5...................................................................................................44
ATTACHMENT B-1...................................................................................................45
ATTACHMENT B-2...................................................................................................46
ATTACHMENT C ....................................................................................................47
ATTACHMENT E.....................................................................................................48
ATTACHMENT E.....................................................................................................49
ATTACHMENT F.....................................................................................................50
ATTACHMENT G.....................................................................................................51
</TABLE>



                                       iv
<PAGE>   6




                                    AGREEMENT



         THIS JOINT VENTURE AGREEMENT ("Agreement") is made and entered into
effective as of August 30, 2000, by and between BIONUMERIK PHARMACEUTICALS,
INC., a Texas corporation, with its office located at 8122 Datapoint Drive,
Suite 1250, San Antonio, Texas 78229, U.S.A. (hereinafter referred to as
"BIONUMERIK") and GRELAN PHARMACEUTICAL CO., LTD., a Japanese corporation having
its place of business at Ogura Bldg. 5F, Nihonbashi Kobunacho 6-6, Chuo-ku,
Tokyo 103-0024, Japan (hereinafter referred to as "GRELAN").

                                    RECITALS:

         WHEREAS, GRELAN and BIONUMERIK intend to create a Delaware limited
liability company to be called KI Pharmaceuticals, L.L.C. (hereinafter referred
to as "KI PHARMA" or the "Venture") for the purpose of developing, marketing,
distributing, manufacturing and selling certain specified products in the
territory of Japan.

         WHEREAS, as described in the organization documents of KI PHARMA, KI
PHARMA will be owned 50% by BIONUMERIK, 49% by GRELAN, and 1% by Dr. Hashime
Kanazawa.

         WHEREAS, additional information describing the ownership, management,
officers, allocation of profits, and other allocations and distributions
regarding KI PHARMA will be contained in an Operating Agreement of KI PHARMA
(the "Operating Agreement"), the terms of which will be agreed to by BIONUMERIK
and GRELAN.

         WHEREAS, GRELAN and BIONUMERIK are parties to a collaboration agreement
dated as of May 28, 1996 and amended as of June 8, 1999 regarding the BNP7787
Products (as defined below) and related technology (the "Existing Agreement")
and the parties wish that GRELAN transfer certain rights it has thereunder to KI
PHARMA, without prejudice to any and all rights GRELAN or BIONUMERIK may retain,
and thereafter the Existing Agreement is immediately terminated, as described in
detail in Section 3.3 below.




<PAGE>   7



         WHEREAS, following creation of KI PHARMA and signing of the Operating
Agreement, KI PHARMA will agree to be bound by the terms of this Agreement.

         WHEREAS, the parties wish to enter into this Agreement to evidence the
license and transfer of certain rights to KI PHARMA and to specify certain
commitments, rights and obligations of the parties in connection with the
Venture.

         WHEREAS, the licenses and other rights granted by GRELAN and BIONUMERIK
herein are granted subject to the obligations to make payments and take other
actions provided by the parties herein.

         NOW, THEREFORE, in consideration of the terms, conditions and
agreements contained herein, and for other good and valuable consideration, the
receipt and adequacy of which are hereby acknowledged, the parties hereto hereby
agree as follows:

         1. DEFINITIONS. When used in this Agreement, each of the following
defined terms shall have the meanings set forth in this Section. There are other
terms defined in this Agreement parenthetically, and such terms shall have the
meanings apparent from the context in which such terms are parenthetically
defined.

               1.1 "BNP7787 Products" means the compounds, pharmaceutical
formulations, and technology described in Attachment A-1 hereto.

               1.2 "Karenitecin Products" means the compounds, pharmaceutical
formulations, and technology described in Attachment A-2 hereto.

               1.3 "[**]" means the pharmaceutical formulations and related
technology described in Attachment A-3 hereto.

               1.4 "PDE4 Products" means the compounds, pharmaceutical
formulations, and technology described in Attachment A-4 hereto.



[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.




                                       2
<PAGE>   8


               1.5 "COX-2 Products" means the compounds, pharmaceutical
formulations, and technology described in Attachment A-5 hereto.

               1.6 "Venture Products BN" means the [**].

               1.7 "Venture Products GR" means the [**].

               1.8 "Venture Products" means the Venture Products BN and the
Venture Products GR.

               1.9 "BioNumerik Improvements" means any and all inventions,
developments, discoveries and improvements directly relating to Venture
Products, including, without limitation, formulae, specifications, designs,
chemical and physical data, clinical data, and information concerning synthesis,
processes, formulations, applications, toxicity, operations, regulatory affairs
and marketing, that are developed by or for BIONUMERIK subsequent to the date of
this Agreement and during the term of this Agreement, subject in all cases to
any restrictions that may exist on the ability of BIONUMERIK to license such
inventions, developments, discoveries or improvements to KI PHARMA and/or
GRELAN, as applicable, in or outside the Territory.

                  1.10 "Grelan Improvements" means any and all inventions,
developments, discoveries, and improvements directly relating to Venture
Products, including, without limitation, formulae, specifications, designs,
chemical and physical data, clinical data, and information concerning synthesis,
processes, formulations, applications, toxicity, operations, regulatory affairs
and marketing, that are developed by or for GRELAN subsequent to the date of
this Agreement and during the term of this Agreement, subject in all cases to
any restrictions that may exist on the ability of GRELAN to license such
inventions, developments, discoveries or improvements to KI PHARMA and/or
BIONUMERIK, as applicable, in or outside the Territory.

               1.11 "Improvements" means the BioNumerik Improvements and the
Grelan Improvements.


[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       3
<PAGE>   9

               1.12 "BioNumerik Patent Rights" means those exclusive rights
granted in Japan to BIONUMERIK, that follow from any of the patent applications
referred to in Attachment B-1 hereto or from any reissue, reexamination,
continuation, divisional, continuation-in-part, utility model, or any other
patent application in Japan of BIONUMERIK whose claimed subject matter covers
any of the Venture Products BN, processes to make any of the Venture Products
BN, or their use. BIONUMERIK's current patent applications in Japan relating to
the Venture Products BN and their uses are identified in Attachment B-1 hereto.

               1.13 "Grelan Patent Rights" means those exclusive rights granted
in Japan to GRELAN, that follow from any of the patent applications referred to
in Attachment B-2 hereto or from any reissue, reexamination, continuation,
divisional, continuation-in-part, utility model, or any other patent application
in Japan of GRELAN whose claimed subject matter covers any of the Venture
Products GR, processes to make any of the Venture Products GR, or their use.
GRELAN's current patent applications in Japan relating to the Venture Products
GR and their uses are identified in Attachment B-2 hereto.

               1.14 "Patent Rights" means the BioNumerik Patent Rights and the
Grelan Patent Rights.

               1.15 "Patents" means those patents embodying the Patent Rights in
the Territory.

               1.16 "Know-How" means all data and information owned by
BIONUMERIK and/or GRELAN, as the case may be, and directly relating to the
Venture Products, including, without limitation, formulae, specifications,
designs, chemical and physical data, clinical data, information concerning
synthesis, processes, formulations, applications, administration to patients,
clinical protocols, toxicity, operations, regulatory affairs and marketing, that
have been developed by or for BIONUMERIK and/or GRELAN, as the case may be, on
or before the date of this Agreement and which is useful in the development,
manufacture or sale of the Venture Product(s) in the Territory, subject in all
cases to any restrictions that may exist on the ability of BIONUMERIK and
GRELAN, as applicable, to license such Know-How to KI PHARMA, BIONUMERIK and/or
GRELAN, as applicable, in or outside the Territory.

               1.17 "Affiliates" means, with respect to each party, any
organization, company, firm, or other entity which controls, is controlled by,
or is under common control with said party. A company shall be deemed to have
control of another if it owns directly or indirectly a majority of the voting
shares of or is entitled directly or indirectly to appoint a majority of the
directors of the other company. ]




                                       4
<PAGE>   10


               1.18 "Confidential Information" means all information which is of
a confidential and proprietary nature, including without limitation, trade
secrets, inventions and unpatented Know-How and Improvements and related
technology, and any and all material information which any of the parties hereto
may acquire concerning the financial, business and marketing goals and plans of
the other parties, including the terms of this Agreement.

               1.19 "Effective Date" means the first date after which all of the
following have occurred: (a) KI PHARMA has been formed, (b) the Operating
Agreement has been signed by GRELAN, BIONUMERIK and Dr. Hashime Kanazawa, (c)
the Stock Purchase Agreement (hereinafter defined) has been signed by GRELAN and
BIONUMERIK and GRELAN has purchased BIONUMERIK preferred stock in accordance
with the terms of the Stock Purchase Agreement, and (d) KI PHARMA has agreed to
be bound as an additional party to this Agreement.

               1.20 "Government Regulatory Approvals" means all government
approvals, health registrations and/or permits, including NDA Approvals,
required for import into or manufacture in the Territory and sale and
distribution in the Territory of Venture Products.

               1.21 "IND Submission" with respect to a Venture Product means
submission of an Investigational New Drug regulatory application ("Chiken
Todoke" corresponding to an IND application in the U.S.) to authorities for
approval to initiate any new phase of human trials of the product in a
jurisdiction in the Territory.

               1.22 "New Drug Application Approval" or "NDA Approval" means
approval from the Japanese Ministry of Health and Welfare or other applicable
regulatory body, as the case may be, of a New Drug Application which authorizes
or allows the import to or manufacture in the Territory of and sale in the
Territory of a Venture Product.

               1.23 "Steering Committee" means the Steering Committee of KI
PHARMA, as such committee is further described in Section 8 hereof.




                                       5
<PAGE>   11



               1.24 "Stock Purchase Agreement" means that certain Stock Purchase
Agreement to be entered into by GRELAN and BIONUMERIK providing for the purchase
by GRELAN of U.S. $4 million of BioNumerik Series G Preferred Stock.

               1.25 "Sublicensee" means an entity to whom KI PHARMA has granted
pursuant to Section 4.3 or 5.1 a sublicense to develop, market, sell, distribute
or otherwise commercially dispose of Venture Products within the Territory,
based on KI PHARMA's exclusive license set forth in Sections 2.2 and 3.2 and its
rights transferred by GRELAN under Section 3.3.

               1.26 "Territory" means Japan and any of its possessions or
territories.

               1.27 "Trademarks" means (i) the brand name(s) selected by KI
PHARMA, with the approval of BIONUMERIK and GRELAN, for Venture Products in the
Territory, and (ii) all Katakana or Hiragana transliterations of the names
referenced above, and all equivalents thereof, for use with Venture Products.

         2. LICENSE GRANTS BY BIONUMERIK.

               2.1 Research and Development Grant. Effective as of the Effective
Date, BIONUMERIK hereby grants to KI PHARMA and GRELAN an exclusive license
under the BioNumerik Patent Rights, Know-How and BioNumerik Improvements to
conduct and have conducted research and development of the Venture Products BN
in the Territory for the purpose of obtaining Government Regulatory Approvals in
the Territory.

               2.2 Grant to Market, Sell and Distribute. Effective as of the
Effective Date, BIONUMERIK hereby grants to KI PHARMA an exclusive license under
the BioNumerik Patent Rights, Know-How, BioNumerik Improvements and Trademarks
to import Venture Products BN into the Territory and/or market, sell, distribute
or otherwise commercially dispose of Venture Products BN in the Territory during
the term of this Agreement. Except as otherwise provided in this Agreement, (a)
BIONUMERIK shall not, without prior written consent from GRELAN, directly or
indirectly, except through KI PHARMA, import Venture Products BN into the
Territory nor distribute or sell Venture Products BN in the Territory, and (b)
KI PHARMA and GRELAN without prior written consent from BIONUMERIK shall not
directly or





                                       6
<PAGE>   12



indirectly manufacture Venture Products BN in the Territory or develop,
manufacture, promote, distribute or sell Venture Products BN outside the
Territory or export Venture Products BN from the Territory.

         3. LICENSE GRANTS AND TRANSFER BY GRELAN.

               3.1 Research and Development Grant. Effective as of the Effective
Date, GRELAN hereby grants to KI PHARMA an exclusive license under the Grelan
Patent Rights, Know-How and Grelan Improvements to conduct and have conducted
research and development of the Venture Products GR in the Territory for the
purpose of obtaining Government Regulatory Approvals in the Territory.

               3.2 Grant to Market, Sell and Distribute. Effective as of the
Effective Date, GRELAN hereby grants to KI PHARMA an exclusive license under the
Grelan Patent Rights, Know-How, Grelan Improvements and Trademarks to market,
sell, distribute or otherwise commercially dispose of Venture Products GR in the
Territory during the term of this Agreement. Except as otherwise provided in
this Agreement, (a) GRELAN shall not directly or indirectly, except through KI
PHARMA, distribute or sell Venture Products GR in the Territory, and (b) KI
PHARMA and BIONUMERIK shall not directly or indirectly develop or manufacture
Venture Products GR in the Territory, import Venture Products GR into the
Territory or develop, manufacture, promote, distribute or sell Venture Products
GR outside the Territory or export Venture Products GR from the Territory.

               3.3 Transfer Regarding Rights Under Existing BNP7787 Agreement.
Effective as of the Effective Date, GRELAN hereby transfers to KI PHARMA all
rights with respect to the import, marketing, sale, distribution or disposal of
the BNP7787 Products under the Existing Agreement. Following the Effective Date,
all other rights and obligations under such Existing Agreement shall terminate,
provided that (i) BIONUMERIK shall have no obligation to repay any amounts
previously paid by GRELAN under such Existing Agreement, (ii) BIONUMERIK shall
continue after the Effective Date to have the right to use all data and results
obtained from the pre-clinical and non-clinical studies and clinical trials
obtained by GRELAN under the Existing Agreement up to the execution of this
Agreement, and (iii) the confidentiality obligations of GRELAN and BIONUMERIK
contained in the Existing Agreement shall remain and continue in full force and
effect in accordance with their terms. In addition, GRELAN shall have the right
to negotiate in the future with KI PHARMA to obtain an exclusive sublicense to
market, sell, promote and distribute (a) the BNP7787 Products in the Territory,
and (b) the PDE4 Products and the COX-2 Products in the Territory and GRELAN
shall retain the exclusive right to develop (i) the BNP7787





                                       7
<PAGE>   13


Products in the Territory and (ii) the PDE4 Products and the COX-2 Products in
the Territory, subject in all cases to GRELAN's performance of product
development in the Territory and the approval rights contained in Section 4.3
hereof (including BIONUMERIK's right to approve the terms of any sublicense by
KI PHARMA to GRELAN of the right to market, sell, promote, distribute or
otherwise commercially dispose of the BNP7787 Products in the Territory).

         4. SUBLICENSES AND OTHER DISTRIBUTION METHODS FOR VENTURE PRODUCTS.

               4.1 Distribution Methods and Branch Office. The method in which
KI PHARMA will market, sell, distribute or otherwise commercially dispose of
Venture Products in the Territory is described in Section 7.3 hereof. If KI
PHARMA establishes or otherwise owns an Affiliate in the Territory, such
Affiliate may become a Sublicensee, subject to the prior written consent of the
parties hereto. A Japanese branch office or other office of KI PHARMA will be
established as quickly as possible after the Effective Date, in the premises of
GRELAN in Nihonbashi, Chuo-ku, Tokyo, Japan.

               4.2 Identification of Sublicensees. [**] (or another designated
qualified senior management employee of GRELAN), at the request of the Steering
Committee, will have the responsibility to identify and present to KI PHARMA
potential third parties to sublicense certain Venture Products for the
Territory.

               4.3 Right to Grant Sublicenses. KI PHARMA shall have the right to
grant sublicenses to market, sell, distribute or otherwise commercially dispose
of Venture Products within the Territory subject to the following conditions:
(i) the parties hereto shall discuss in good faith with respect to the timing of
a formal request and authorization to pursue any potential sublicense by KI
PHARMA with respect to Venture Products but BIONUMERIK shall have the right to
decide such timing with respect to Venture Products BN, and GRELAN shall have
the right to decide such timing with respect to Venture Products GR; (ii) in
addition, (a) BIONUMERIK will have the final right and authority to accept or
refuse any potential Sublicensee for Venture Products BN in the Territory, and
(b) GRELAN will have the final right and authority to accept or refuse any
potential Sublicensee for Venture Products GR in the Territory; provided that if
GRELAN is the potential Sublicensee for a particular Venture Product GR, then
the

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       8
<PAGE>   14




Steering Committee shall have the final right and authority to accept or refuse
such sublicense, and provided further that BIONUMERIK and GRELAN shall not
refuse such Sublicensees unreasonably.

               4.4 Division of Sublicensing Fees and Other Payments. In
consideration for the valuable nature of the Patent Rights, Know-How and
Improvements and the access to potential new partners they will give to KI
PHARMA, (i) in the event a sublicense fee or other up-front or milestone payment
amount due on or before the relevant NDA Approval (collectively, the "Up-front
Payment") is paid by any Sublicensee or other third party for distribution,
marketing and/or sales rights to a Venture Product BN in the Territory, then
[**], and (ii) in the event the Up-front Payment is paid by any Sublicensee or
other third party for distribution, marketing and/or sales rights to a Venture
Product GR in the Territory, then [**]. All royalty payments due after the
relevant NDA Approval (the "Royalties") and any additional amounts received from
any Sublicensee or other third party in connection with a Venture Product being
sold by or for the benefit of KI PHARMA [**].

               4.5 Third Party Offers or Statements of Interest. If a third
party makes a statement of interest or offer to sublicense a Venture Product in
the Territory to any of the parties hereto, then the notified party shall notify
the other parties hereto with respect to the indication of interest or offer and
shall provide the other parties hereto with copies of any correspondence and a
summary of any meeting regarding such matter.

         5. RIGHTS OF FIRST REFUSAL FOR VENTURE PRODUCTS BN AND DEVELOPMENT
            RIGHTS.

               5.1 Right of First Refusal. Subject to the conditions contained
in Section 4.3, effective as of the Effective Date GRELAN is hereby granted by
KI PHARMA a right of first refusal to negotiate to obtain a license for itself
for any Venture Products BN that KI PHARMA proposes to license to third parties.
The first refusal right granted herein with respect to each particular product
will expire forty- five (45) days after GRELAN's receipt of a written notice
from KI PHARMA identifying such Venture Product BN proposed to be licensed to a
third party. If no proposal to obtain a license for such product is made to KI
PHARMA by GRELAN within such time period, GRELAN's right of first refusal shall


[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.


                                       9
<PAGE>   15




terminate with respect to such product. In the event GRELAN does make a proposal
for the product within such time period, then KI PHARMA, GRELAN, and BIONUMERIK
will negotiate in good faith during the remainder of such 45 day notice period
and for an additional 90 day period (the "Negotiation Period") in an effort to
enter into a license agreement for such product on mutually agreeable terms. If
a license has not been executed by the end of the Negotiation Period, then (i)
the negotiations shall be deemed deadlocked and KI PHARMA shall, upon the
request of BIONUMERIK, use best efforts to seek another potential licensee with
respect to such product, and (ii) KI PHARMA shall be free to enter into such
third party license, provided the terms of such license are no more favorable to
such third party licensee than the terms last proposed to GRELAN.

               5.2 Development Rights. Effective as of the Effective Date, KI
PHARMA shall have the right, with the right to sublicense, to develop all
Venture Products in the Territory in accordance with the terms of this Agreement
and with the assistance of GRELAN as provided herein. Unless otherwise agreed by
the parties, BIONUMERIK will have the right to develop all Venture Products BN
outside of the Territory and GRELAN will have the right to develop all Venture
Products GR outside of the Territory. BIONUMERIK shall be solely responsible for
its licensing or development activities concerning Venture Products BN outside
the Territory.

               5.3 Development Outside Territory. Upon future mutual written
agreement by BIONUMERIK and GRELAN and if such rights are then available, KI
PHARMA may market, sell and distribute certain specified Venture Products in
other parts of Asia in addition to Japan. Notwithstanding the foregoing, GRELAN
shall remain free to license the rights to Venture Products GR outside of the
Territory in its sole discretion without the consent or approval of KI PHARMA or
BIONUMERIK; and BIONUMERIK shall remain free to license the rights to Venture
Products BN outside the Territory in its sole discretion without the consent or
approval of KI PHARMA or GRELAN. In addition to the foregoing, nothing in this
Agreement shall impact or restrict (a) the ability of GRELAN to develop, market,
sell, distribute, license, or otherwise commercially dispose of Venture Products
GR outside of the Territory in its sole discretion without the consent or
approval of KI PHARMA or BIONUMERIK, or (b) the ability of BIONUMERIK to
develop, market, sell, distribute, license, or otherwise commercially dispose of
Venture Products BN outside of the Territory in its sole discretion without the
consent or approval of KI PHARMA or GRELAN.




                                       10
<PAGE>   16




         6. INFORMATION SHARING AND DEVELOPMENT COSTS.

               6.1 Pre-Clinical Studies. GRELAN agrees at its sole expense to
sponsor and conduct (or have sponsored and conducted) all necessary additional
pre-clinical and non-clinical studies and tests required by the Japanese
Ministry of Health and Welfare (the "MHW") or other local regulatory agency in
the Territory in connection with commencing and conducting human clinical trials
with respect to the Venture Products in the Territory and with respect to the
manufacture (or importation into the Territory), sale and distribution of
Venture Products in the Territory. BIONUMERIK will provide free of charge to KI
PHARMA and GRELAN all pre-clinical data, clinical research protocols, and
clinical trials data and information previously or hereafter developed by
BIONUMERIK that were used and/or are necessary to support United States Food and
Drug Administration ("FDA") regulatory submissions to support regulatory
applications for the Venture Products BN in the Territory. GRELAN will provide
free of charge to KI PHARMA and BIONUMERIK all pre-clinical data, clinical
research protocols, and clinical trials data and information previously or
hereafter developed by GRELAN that are necessary to support regulatory
submissions to support regulatory applications for the Venture Products GR in
the Territory.

         6.2 Government Approvals and Clinical Trials.

               6.2.1. GRELAN agrees to (a) conduct or cause to be conducted all
clinical trials and other studies of any nature of the Venture Products
necessary or desirable for efficiently obtaining Government Regulatory Approvals
in the Territory and (b) prepare and submit all documents necessary or desirable
for obtaining Government Regulatory Approvals in the Territory. GRELAN shall be
solely responsible for paying the costs of such clinical development and
regulatory approvals described in the previous sentence and GRELAN shall
reimburse KI PHARMA for all costs of any such clinical development and
regulatory approvals paid by KI PHARMA. If permitted by laws in the Territory,
the Government Regulatory Approvals for Venture Products shall be obtained in
the name of KI PHARMA, and GRELAN shall provide such additional assistance as
may be necessary to assure that such Approvals are obtained in the name of KI
PHARMA. Such assistance shall include, without limitation, acting as an agent of
KI PHARMA where necessary to facilitate the regulatory process. If the
Government Regulatory Approvals are not permitted to be obtained by KI PHARMA in
the name of KI PHARMA, then, with the consent of GRELAN and BIONUMERIK (which
consent will not be unreasonably withheld) such approvals will be obtained in
the name of GRELAN. To the extent permitted by laws in the Territory,



                                       11
<PAGE>   17




BIONUMERIK agrees to assist and support the process of obtaining the Government
Regulatory Approvals by providing input and assistance from Dr. Frederick H.
Hausheer regarding the design and conduct of preclinical experiments, clinical
protocols and trials, preparation of regulatory submissions and review, analysis
and presentation of laboratory and other non-clinical data. BIONUMERIK shall
have the right to review all draft and final clinical protocols prior to
initiation of any clinical trial in the Territory for Venture Products BN.

               6.2.2. GRELAN shall provide BIONUMERIK and KI PHARMA with copies
of all data and developments which arise from research and development carried
out on the Venture Products pursuant to Sections 6.1 and 6.2.1. KI PHARMA shall
have ownership (including reservation of the right to use in the Territory in
accordance with this Agreement) of all data and results obtained by GRELAN or KI
PHARMA from the pre-clinical and non-clinical studies and clinical trials
pursuant to Sections 6.1 and 6.2.1 (the "Data and Results"). Unless otherwise
agreed by the parties hereto, without any further payment, BIONUMERIK is granted
the non-exclusive right, with the right to sublicense, to use the Data and
Results related to Venture Products BN outside the Territory for the purpose of
supporting pre-clinical studies, clinical trials and product regulatory approval
and development in areas outside the Territory. Unless otherwise agreed by the
parties hereto, without any further payment, GRELAN is granted the non-exclusive
right, with the right to sublicense, to use the Data and Results related to
Venture Products GR outside the Territory for the purpose of supporting
pre-clinical studies, clinical trials and product regulatory approval and
development in areas outside the Territory. In addition, without any further
payment, KI PHARMA and GRELAN may use the Data and Results to support the
development, sale and distribution of Venture Products in the Territory (and in
other parts of Asia subject to Section 5.3) in accordance with this Agreement
during the term of this Agreement.

               6.2.3. BIONUMERIK shall comply with applicable Japanese
Pharmaceutical Law and any other applicable governmental requirements in the
Territory regarding manufacture in and import into the Territory and development
and marketing in the Territory of the Venture Products, with relation to actions
by BIONUMERIK.




                                       12
<PAGE>   18





         6.3 Copies and Provision of Information.

               6.3.1. KI PHARMA and GRELAN will keep BIONUMERIK regularly and
fully informed of the preclinical and clinical process regarding the Venture
Products. KI PHARMA and GRELAN also shall keep BIONUMERIK regularly and fully
informed of the status of the Government Regulatory Approvals process on a
current basis and furnish BIONUMERIK, upon BIONUMERIK's reasonable request, with
English version copies of all important documents, data and other information
supplied to or received from the Japanese Government or other approval authority
in connection with the applications for the Government Regulatory Approvals.
Upon receipt of each Government Regulatory Approval, KI PHARMA and GRELAN shall
promptly furnish BIONUMERIK English version copies or other satisfactory
evidence thereof.

               6.3.2. BIONUMERIK shall provide KI PHARMA and GRELAN with copies
of all information generated or controlled by it in the course of satisfying
regulatory requirements in the United States and/or Europe related to any
Venture Products BN that may be useful or necessary in obtaining Government
Regulatory Approvals in the Territory, such as IND applications, annual reports,
protocol amendments, IND amendments, and related documents ("IND and Related
Information"). If BIONUMERIK grants a license for commercial distribution of any
Venture Products BN in areas outside the Territory, BIONUMERIK agrees to use its
best efforts to provide in any agreement hereinafter signed with respect to such
license that the licensee under such license shall provide KI PHARMA and GRELAN
with all data and information generated by such licensee with respect to such
products for supporting the development of such products in the Territory.
GRELAN shall provide KI PHARMA and BIONUMERIK with copies of all information
generated or controlled by it in the course of satisfying regulatory
requirements in the United States and/or Europe related to Venture Products GR
that may be useful or necessary in obtaining Governmental Regulatory Approvals
in the Territory, such as IND and Related Information. If GRELAN grants a
license for commercial distribution of any Venture Products GR in areas outside
the Territory, GRELAN agrees to use its best efforts to provide in any agreement
hereinafter signed with respect to such license that the licensee under such
license shall provide KI PHARMA and BIONUMERIK with all data and information
generated by such licensee with respect to such products for supporting the
development of such products in the Territory. In the event a prospective
licensee for the commercial distribution of Venture Products in areas outside
the Territory will not agree to the sharing of all data and information as
provided above, each of BIONUMERIK and GRELAN will consult with KI PHARMA prior
to signing any license agreement with such party and each of BIONUMERIK and




                                       13
<PAGE>   19

GRELAN will use its best efforts to facilitate and provide an opportunity for
discussion among GRELAN, BIONUMERIK and such prospective licensee with respect
to a mutually satisfactory arrangement for the sharing of data and information.
For purposes of this provision, "best efforts" shall mean those reasonable
commercial efforts that would be used by reasonable business persons in a
similar situation.

               6.3.3 GRELAN and KI PHARMA will provide BIONUMERIK with
marketing, pricing, patent, product and distribution information regarding the
Venture Products and any potentially competitive products in the Territory,
except to the extent restricted by law, other licenses or similar agreements to
which GRELAN is a party. BIONUMERIK and KI PHARMA will provide GRELAN with
marketing, pricing, patent, product and distribution information regarding the
Venture Products and any potentially competitive products outside the Territory,
except to the extent restricted by law, other licenses or similar agreements to
which BIONUMERIK is a party.

               6.4 Supplies of Product for Pre-Clinical Studies and Clinical
Trials. If requested by KI PHARMA and/or GRELAN, all supplies of Venture
Products BN required by GRELAN and/or KI PHARMA in order to conduct the studies
described in Sections 6.1 and 6.2 shall be furnished by BIONUMERIK to GRELAN
and/or KI PHARMA at a price equal to [**]. In accordance with Sections 6.1 and
6.2, GRELAN shall be responsible for paying all such costs described in this
Section 6.4.

               6.5 Provision of Know-How. As soon as practicable after the
Effective Date, and on a regular basis thereafter during the term of this
Agreement, each of BIONUMERIK and GRELAN will, subject to the confidentiality
and other limitations contained herein, provide its Know-How and will thereafter
provide its Improvements to KI PHARMA (and GRELAN as well in the case where
BIONUMERIK will provide such Know-How and Improvements) for the purpose of
enabling GRELAN and KI PHARMA to conduct the studies described in Sections 6.1
and 6.2, and otherwise to support Government Regulatory Approvals and the
marketing of Venture Products in the Territory in accordance with the terms of
this Agreement.




[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       14
<PAGE>   20



7.   MANUFACTURING RIGHTS FOR VENTURE PRODUCTS AND PURCHASE OF APPROVED
     PRODUCTS BY THE VENTURE.

         7.1 Manufacturing Rights for Venture Products BN.

               7.1.1 BIONUMERIK will retain all manufacturing rights for Venture
Products BN. Any other terms and conditions regarding the sale or provision of
Venture Products BN by BIONUMERIK to KI PHARMA or a designated third party will
be separately agreed by the parties hereto after taking into account the
scenarios and illustrations contained on Attachment C hereto and the other
factors and considerations described in this Section. BIONUMERIK has the right
to manufacture Venture Products BN directly or to establish a contract with a
third party manufacturer to supply KI PHARMA or the designated third party
licensee for product distribution in the Territory. GRELAN shall help BIONUMERIK
to identify and recommend key qualified GMP manufacturers) in the Territory who
would be appropriate as such manufacturer. Upon receiving the appropriate
Government Regulatory Approvals for any Venture Products BN, KI PHARMA (or if
agreed to by the parties hereto, a KI PHARMA subsidiary or affiliate or a
designated third party) will directly purchase Venture Products BN from
BIONUMERIK at a specified sales price (the "BioNumerik Sales Price") in
accordance with the Supply Arrangements referred to in Section 7.4. The
BioNumerik Sales Price will be decided by the parties hereto in good faith
taking into account the following factors and considerations:

               (a) [**];

               (b) [**];

               (c) [**];

               (d) [**]; and

               (e) [**].




[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.




                                       15


<PAGE>   21


         7.1.2 [**]:

               (a) [**]

               (b) [**].

         7.2 Manufacturing Rights for Venture Products GR.

               7.2.1 GRELAN will retain all manufacturing rights for Venture
Products GR. Any other terms and conditions regarding the sale or provision of
Venture Products GR by GRELAN to KI PHARMA will be separately agreed by the
parties hereto after taking into account the scenarios and illustrations
contained on Attachment C hereto and the other factors and considerations
described in this Section. GRELAN has the right to manufacture Venture Products
GR directly or to establish a contract with a third party manufacturer to supply
KI PHARMA or the designated third party licensee for product distribution in the
Territory. Upon receiving the appropriate Government Regulatory Approvals for
any Venture Products GR, KI PHARMA (or if agreed to by the parties hereto, a KI
PHARMA subsidiary or affiliate or a designated third party) will directly
purchase Venture Products GR from GRELAN at a specified sales price (the "Grelan
Sales Price") in accordance with the Supply Arrangements referred to in Section
7.4. The Grelan Sales Price will be decided by the parties hereto in good faith
taking into account the following factors and considerations:

               (a) [**];

               (b) [**];

               (c) [**];

               (d) [**]

               (e) [**].


[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       16
<PAGE>   22


               7.2.2 [**]

               (a) [**]

               (b) [**]

         7.3 Distribution and Sale of Venture Products.

         Based on the foregoing considerations, Venture Products will be
distributed and sold through one or more of the following methods:

               (a) [**]

               (b) [**]

               (c) [**]

[**]

               7.4 Commercial Supply Arrangements. Within [**] months prior to
the estimated time of the first commercial sale of a particular Venture Product
in the Territory, GRELAN (if such product is a Venture Product GR) or BIONUMERIK
(if such product is a Venture Product BN) shall enter into a commercial supply
agreement or make other appropriate arrangements (the "Supply Arrangements ")
with KI PHARMA to be negotiated in good faith by KI PHARMA, BIONUMERIK and
GRELAN and to reflect such terms and conditions as shall be reasonably necessary
to provide adequate supply of such Venture Product for sale and distribution in
the Territory.




[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       17
<PAGE>   23


               7.5 Product Labeling. Unless otherwise agreed to by GRELAN, all
labeling for Venture Products GR shall recognize that such products are
distributed under license from GRELAN. Unless otherwise agreed to by BIONUMERIK,
all labeling for Venture Products BN shall recognize that such products are
distributed under license from BIONUMERIK. One or more of KI PHARMA, GRELAN and
BIONUMERIK may be named on labeling for specified Venture Products as may be
agreed from time to time by all the parties hereto.

         8. STEERING COMMITTEE.


               8.1 Formation and Composition. Promptly following the Effective
Date, a Steering Committee of KI PHARMA will be established with responsibility
for the overall management of the development, manufacture, licensing
activities, distribution and marketing of the Venture Products in the Territory
in accordance with the terms of this Agreement. The Steering Committee shall be
comprised of two members, one appointed by GRELAN and one appointed by
BIONUMERIK, both of whom shall be cochairmen of the Steering Committee and
"Managers" of KI PHARMA (as defined in the Operating Agreement). Each Steering
Committee member should be a senior qualified full-time employee who serves as a
manager for his respective company and who has extensive knowledge of
pharmaceutical operations. [**] will be the founding Steering Committee members
who will co-chair the Steering Committee.

               8.2 Duties. The Steering Committee shall have such duties and
responsibilities as are provided in the Operating Agreement. No Steering
Committee member shall be removed and no new Steering Committee member shall be
appointed unless such removal or appointment is consented to by both GRELAN and
BIONUMERIK.

               8.3 Meetings. The Steering Committee will meet at least quarterly
(in Japan, U.S. or by telephone, video conference or internet - by mutual
consent) to review the progress of the development of Venture Products in the
Territory.

               8.4 Recommendation Regarding Management. The Steering Committee
will recommend management and key personnel to KI PHARMA for development,
manufacturing, regulatory, marketing, distribution and sale of Venture Products
in the Territory, at their request.


[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       18
<PAGE>   24


               8.5 Identification of Consultants. If needed, the Steering
Committee shall identify third party consultants and contractors to assist in
the development of the Venture Products in the Territory.


         9. DEVELOPMENT AND COMMERCIALIZATION PLAN.

               9.1 General Diligence Efforts. The parties hereto agree to use
their best efforts to commercialize or cause to be commercialized the Venture
Products in the Territory as soon as reasonably practicable.

               9.2 Target Development and Commercialization Plan. In addition to
the above general diligence requirements, KI PHARMA shall meet the target
development and commercialization plan for Venture Products. The target
development and commercialization plan for the BNP7787 Products is set forth in
Attachment D hereto, and those for the other Venture Products shall be decided
by the parties hereto as soon as reasonably practical. These target development
and commercialization plans will be updated on a semi-annual basis by the
Steering Committee. If any of the specified targets are not met with respect to
a particular Venture Product, and such targets continue to remain unmet for a
period of [**] or greater following notice to the parties by any party
hereunder, then the parties hereto shall discuss and decide in good faith how to
solve the problem. [**]. An extension of the time to meet the development
performance requirements in the previous sentence may be granted upon mutual
agreement between GRELAN and BIONUMERIK.

         10. PATENT MATTERS.

               10.1 BioNumerik Patent Maintenance. BIONUMERIK will be
responsible for prosecuting and maintaining Patents for Venture Products BN at
its own expense and BIONUMERIK will own all Patent Rights for Venture Products
BN. BIONUMERIK shall advise GRELAN as to the progress of its patent applications
and registrations in Japan relating to Venture Products BN from time to time. In
addition, BIONUMERIK will advise GRELAN as to patent strategy and prosecution
outside the Territory with respect to Venture Products BN.



[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.


                                       19
<PAGE>   25

               10.2. GRELAN Patent Maintenance and Assistance. GRELAN will be
responsible for prosecuting and maintaining Patents for Venture Products GR at
its own expense and GRELAN will own all Patent Rights for Venture Products GR.
GRELAN shall advise BIONUMERIK as to the progress of its patent applications and
registrations in Japan relating to the Venture Products GR from time to time. In
addition, GRELAN will advise BIONUMERIK as to patent strategy and prosecution in
the Territory with respect to Venture Products BN.

               10.3. No Present Notification of Infringement-BioNumerik. Except
as described in Attachment E hereto, BIONUMERIK represents and warrants to KI
PHARMA and GRELAN that BIONUMERIK has not received any notification of, and has
no knowledge that the use by KI PHARMA and GRELAN of the Know-How or the
manufacture, use or sale of the Venture Products BN infringes any third party
patent rights in the Territory. If during the term of this Agreement an
infringement action should be brought in the Territory by a third party against
KI PHARMA or GRELAN or their Affiliates or sublicensees claiming that the use of
the Know-How or the Improvement relating to the Venture Products BN or the
manufacture, use or sale of the Venture Products BN licensed hereunder infringes
any patent rights of the third party in the Territory, KI PHARMA and/or GRELAN
will promptly inform BIONUMERIK of such fact in writing and BIONUMERIK agrees to
consult with KI PHARMA and GRELAN in order to decide together the course of
action which should be taken in such case. Each of the parties hereto agrees to
cooperate fully in any defense against such infringement action. All legal
expenses and costs (including attorneys' fee) in such defense shall be borne
[**].









[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.


                                       20
<PAGE>   26


               10.4. No Present Notification of Infringement- Grelan. Except as
described in Attachment E hereto, GRELAN represents and warrants to KI PHARMA
and BIONUMERIK that GRELAN has not received any notification of, and has no
knowledge that the use by KI PHARMA and GRELAN of the Know-How or the
manufacture, use or sale of the Venture Products GR infringes any third party
patent rights in the Territory. If during the term of this Agreement an
infringement action should be brought in the Territory by a third party against
KI PHARMA or GRELAN or their Affiliates or sublicensees claiming that the use of
the Know-How or the Improvement relating to the Venture Products GR or the
manufacture, use or sale of the Venture Products GR licensed hereunder infringes
any patent rights of the third party in the Territory, KI PHARMA and/or GRELAN
will promptly inform BIONUMERIK of such fact in writing and GRELAN agrees to
consult with KI PHARMA and BIONUMERIK in order to decide together the course of
action which should be taken in such case. Each of the parties hereto agrees to
cooperate fully in any defense against such infringement action. All legal
expenses and costs (including attorneys' fee) in such defense shall be borne
[**].

         10.5. Enforcement of Patents and Proprietary Rights.

               (a) If allowable by law, KI PHARMA, as exclusive licensee for the
Venture Products in the Territory, shall have power to institute and prosecute
proceedings or suits ("Suits") for infringement of the Patent Rights and/or
Patents and proprietary rights regarding Venture Products in the Territory.
BIONUMERIK may join and, if required by law, BIONUMERIK will join as party
plaintiff in such Suits regarding Venture Products BN. In addition, KI PHARMA
shall not institute or settle any Suit regarding Venture Products BN without the
consent of BIONUMERIK (which consent will not be unreasonably withheld) and
BIONUMERIK may assume control of any Suit regarding Venture Products BN at its
own expense by giving notice to KI PHARMA and agreeing to be responsible for all
further costs of such Suit. GRELAN may join and, if required by law, GRELAN will
join as party plaintiff in such Suits regarding Venture Products GR. In
addition, KI PHARMA shall not institute or settle any Suit regarding Venture
Products GR without the consent of GRELAN (which consent will not be
unreasonably withheld) and GRELAN may assume control of any Suit regarding
Venture Products GR at its own expense by giving notice to KI PHARMA and
agreeing to be responsible for all further costs of such Suit.



[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       21
<PAGE>   27


               (b) Except as otherwise expressly provided herein, all legal
expenses and costs (including attorneys' fee) in such Suits and all other
third-party patent litigation regarding the Venture Products in the Territory
(the "Legal Expenses") will be borne 50% by GRELAN and 50% by BIONUMERIK.

               (c) All recoveries in any Suit (including attorneys' fee) and all
other third-party patent litigation regarding the Venture Products in the
Territory (regardless of which party actually receives such recovery) shall be
applied first in or toward satisfaction of all expenses borne by GRELAN and
BIONUMERIK in connection with such Suit or other patent litigation. If any
surplus remains it shall (i) be paid in full to BIONUMERIK if the Suit or other
patent litigation is related to Venture Products BN or (2) be paid in full to
GR-ELAN if the Suit or other patent litigation is related to Venture Products
GR.

               (d) KI PHARMA shall give BIONUMERIK and GRELAN full and complete
access to all information BIONUMERIK or GRELAN reasonably request related to the
Suits.

         11. IMPROVEMENTS.

               11.1 BioNumerik Improvements Included. Following the Effective
Date and during the term of this Agreement, without any further payment,
BIONUMERIK shall promptly and fully disclose and grant (a) an exclusive
royalty-free license to KI PHARMA to use any BioNumerik Improvements in the
Territory for the purpose of development and commercialization of the Venture
Products in the Territory in accordance of this Agreement, and (b) a
non-exclusive royalty free license to GRELAN to use such Improvements in the
Territory for the purpose of development of Venture Products in the Territory in
accordance with this Agreement. In addition, BIONUMERIK hereby grants GRELAN
effective as of the Effective Date (a) a non-exclusive, perpetual, fully paid-up
royalty-free license, with the right to sublicense, to use all BioNumerik
Improvements related only to Venture Products GR outside the Territory for the
purpose of development and commercialization of such products outside the
Territory, and (b) a nonexclusive, perpetual (but only after the expiration or
termination of this Agreement), fully paid-up royaltyfree license, with the
right to sublicense, to use such BioNumerik Improvements related only to Venture
Products GR in the Territory for the purpose of development and
commercialization of such products in the Territory.




                                       22
<PAGE>   28


               11.2. Grelan Improvements Included. Following the Effective Date
and during the term of this Agreement, without any further payment, GRELAN shall
promptly and fully disclose and grant an exclusive royalty-free license to KI
PHARMA to use any Grelan Improvements in the Territory for the purpose of
development and commercialization of Venture Products in the Territory in
accordance with this Agreement. In addition, GRELAN hereby grants to BIONUMERIK
effective as of the Effective Date (a) a non-exclusive, perpetual, fully paid-up
royalty-free license, with the right to sublicense, to use all Grelan
Improvements related only to Venture Products BN outside the Territory for the
purpose of development and commercialization of such products outside the
Territory and (b) a non-exclusive, perpetual (but only after the expiration or
termination of this Agreement), fully paid-up royalty-free license, with the
right to sublicense, to use such Grelan Improvements related only to Venture
Products BN in the Territory for the purpose of development and
commercialization of such products in the Territory.

               11.3. Joint Improvements. Any new intellectual property generated
by KI PHARMA shall be jointly owned by BIONUMERIK and GRELAN on an equal basis.
Each of BIONUMERIK and GRELAN hereby agrees to license its interest in such
intellectual property in the manner provided in Sections 11.1 and 11.2.

               11.4. Sublicense of Improvements. The sublicense by KI PHARMA of
the rights to any BioNumerik Improvements in the Territory shall require the
written prior approval of BIONUMERIK, and the sublicense by KI PHARMA of the
rights to any Grelan Improvements in the Territory shall require the written
prior approval of GRELAN.




                                       23
<PAGE>   29



         12. TRADEMARKS AND TRADEMARK RIGHTS.

               12.1. KI PHARMA shall register and maintain the Trademarks for
the benefit and at the expense of KI PHARMA for use in and association with
Venture Products in the Territory. GRELAN agrees to assist in such registration,
if requested by KI PHARMA or BIONUMERIK. KI PHARMA shall sell the Venture
Products only under the Trademarks.

               12.2. GRELAN shall be the exclusive owner of all Trademarks and
trademark registrations associated with Venture Products GR, and BIONUMERIK
shall be the exclusive owner of all Trademarks and trademark registrations
associated with Venture Products BN. GRELAN shall remain free to use and grant
rights to the use of the Trademarks outside of the Territory with respect to
Venture Products GR. BIONUMERIK shall remain free to use and grant rights to the
use of the Trademarks outside of the Territory with respect to Venture Products
BN.

               12.3. KI PHARMA shall maintain the quality control standards set
forth by GRELAN and BIONUMERIK from time to time with respect to the Trademarks;
and KI PHARMA will ensure that any Sublicensee using the Trademarks in the
Territory shall be subject to similar standards of quality control.

         13. CONFIDENTIALITY.

               13.1. Confidential and Proprietary Information. Each party hereto
acknowledges that in order for the parties to carry out their respective
obligations under this Agreement, it may be necessary for the parties to
disclose to each other certain Confidential Information. Each party hereto
agrees:

                     13.1.1. To ensure that it does not reveal or make
available to any third party any Confidential Information of any other party,
except as such disclosure may be expressly authorized by this Agreement or
otherwise specifically approved in writing by the party against whom such
disclosure is sought and to ensure that it will treat such Confidential
Information of each other party in the same manner as it treats its own
Confidential Information, such treatment to be at least the degree that a
reasonable person would perform under similar circumstances;




                                       24
<PAGE>   30


               13.1.2. To ensure that Affiliates, sublicensees, employees,
agents, associates or other persons to whom such disclosure may be made or who
may otherwise have access to such Confidential Information of any other party
have agreed in writing to safeguard and maintain such Confidential Information
of the other party or parties in confidence;

               13.1.3. To ensure that Confidential Information of the other
party or parties is not used for the receiving party's benefit except as such
benefits are expressly contemplated herein;

               13.1.4. To prohibit the Confidential Information of the other
party or parties from being duplicated in any manner; except as is reasonably
necessary to perform the tasks and obligations contemplated under this
Agreement; and

               13.1.5. To prohibit the Confidential Information of the other
party or parties from being published in any form without the express written
consent of the disclosing party.

         13.2. Matters not Included as Confidential Information.
Notwithstanding anything herein to the contrary, the defined term "Confidential
Information" and the obligations of nondisclosure, nonuse and confidentiality
relating thereto shall not include any information or data which:

               13.2.1. Is or becomes known to the general public through no
action or fault of the receiving party;

               13.2.2. Was already known to the receiving party prior to the
date of disclosure hereunder, as evidenced by the written records of that party,
without any obligation of confidentiality;

               13.2.3. Is or becomes known to the receiving party without any
obligation of confidentiality from a third party having the right to disclose
the same, and not having a confidential relationship with the disclosing party
with respect thereto; or

               13.2.4. Is necessary for the receiving party or its Affiliates to
disclose to a governmental authority or any agency thereof on a non-confidential
basis, in order to pursue Government Regulatory Approvals or other regulatory
approvals as contemplated by this Agreement or for other


                                       25

<PAGE>   31


purposes related to the intent of this Agreement; provided, however, that the
receiving party shall notify the disclosing party before disclosing such
Confidential Information.

               13.3. Survival of Confidentiality. The obligations of this
Section 13 with respect to Confidential Information shall continue during the
term of this Agreement and for 10 years after the termination or expiration of
this Agreement.


         14. PROVISION FOR VENTURE FUNDING.

         GRELAN and BIONUMERIK shall provide KI PHARMA with reasonable funding
in proportion to their ownership interest in KI PHARMA immediately before such
funding so that KI PHARMA is adequately funded for its ongoing business and
taxes. Such funding shall be provided or obtained in such form and in such
manner as may be agreed between GRELAN and BIONUMERIK, but for the avoidance of
doubt, may include contribution of additional capital, member loans or member
guarantees for borrowing from third parties. [**].

         15. ACCOUNTING.

               KI PHARMA shall keep and shall cause its Sublicensees to keep
written (English) records and reports relating to the transactions covered by
this Agreement. As soon as practicable after the end of each fiscal year of KI
PHARMA, and in any event within 60 days thereafter, KI PHARMA shall prepare or
cause to be prepared, audited financial statements of KI PHARMA as of the end of
and for such fiscal year, including balance sheets, statements of operations,
and statements of cash flow, all of which will be prepared in accordance with
generally accepted accounting principles consistently applied during the periods
covered thereby and setting forth in each case in comparative form the figures
for the previous fiscal year, all in reasonable detail and audited by
independent public accountants of internationally recognized standing selected
by KI PHARMA, BIONUMERIK, and GRELAN. As soon as practicable after the end of
the first, second, and third quarterly accounting periods in each fiscal year of
KI PHARMA and in any event within




[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.


                                       26
<PAGE>   32

30 days thereafter, KI PHARMA shall prepare or cause to be prepared, a balance
sheet of KI PHARMA as of the end of each such quarterly period, and statements
or operations and statements of cash flow of KI PHARMA, for such period and for
the current fiscal year to date, prepared in accordance with generally accepted
accounting principles consistently applied during the periods covered thereby
(other than for accompanying notes), subject to changes resulting from year-end
audit adjustments, and setting forth in each case the comparative figures for
the previous fiscal year, all in reasonable detail. All such prepared
documentation referred to herein will be provided by KI PHARMA to BIONUMERIK and
GRELAN without charge. Upon the request of either BIONUMERIK or GRELAN, and on
reasonable notice, KI PHARMA shall and shall cause its Affiliates and
Sublicensees to permit, at the expense of the requesting party (BIONUMERIK or
GRELAN, as the case may be), an independent certified public accountant
reasonably acceptable to KI PHARMA and the requesting party, to have access
during reasonable business hours to such records as may be necessary to (a)
obtain any additional information and records as may be required to prepare
audited financial information for KI PHARMA or as may be otherwise required to
comply with financial reporting and disclosure requirements of such party, and
(b) determine the correctness of any fee or payment statements and actual
payments made under this Agreement. Each of BIONUMERIK and GRELAN undertakes and
agrees that neither BIONUMERIK nor GRELAN nor any certified public accountant
selected by either of them pursuant to this Section shall disclose any
information so obtained except as required by law or to the extent necessary to
enforce this Agreement.

               16. USE OF NAMES. The parties hereto understand that each of
BIONUMERIK, GRELAN, and KI PHARMA may disclose certain matters pertaining to
this Agreement which may include the names of KI PHARMA, GRELAN and BIONUMERIK,
and the subject matter of this Agreement, if and to the extent that such
disclosure is required by the applicable securities laws or other applicable
laws and regulations; provided, however, that if such disclosure is made in the
form of public statements, whether oral or written, including, but not limited
to, shareholder reports, communications with stock market analysts, press
releases or other communications with the media, the disclosing party must
obtain the prior written approval of the other parties (which approval shall not
be unreasonably withheld) and further provided that no incorrect, exaggerated or
misleading statements shall be disclosed.



                                       27
<PAGE>   33



         17. INDEMNIFICATION.


               17.1. BioNumerik Indemnification. BIONUMERIK agrees to defend,
indemnify and hold harmless GRELAN and KI PHARMA from and against any and all
(a) product liability and related costs and expenses (including attorney fees)
arising out of Venture Products BN supplied by BIONUMERIK and (b) all other
claims, damages or costs, including attorney fees, arising out of manufacturing
defects of any Venture Products supplied by BIONUMERIK, or the negligence,
failure to follow established good manufacturing practices or International
Conference on Harmonization (ICH) guidelines, or non-compliance with applicable
laws and regulations in the Territory on the part of BIONUMERIK.

               17.2. Grelan Indemnification. GRELAN agrees to defend, indemnify
and hold harmless BIONUMERIK and KI PHARMA from and against any and all (a)
product liability and related costs and expenses (including attorney fees)
arising out of Venture Products GR supplied by GRELAN and (b) all other claims,
damages or costs, including attorney fees, arising out of manufacturing defects
of any Venture Products supplied by GRELAN, or the negligence, failure to follow
established good manufacturing practices or ICH guidelines, or non-compliance
with applicable laws and regulations in the Territory on the part of GRELAN.

               17.3. KI Pharma Indemnification. Notwithstanding the provisions
of Sections 17.1 and 17.2, KI PHARMA shall defend, indemnify and hold harmless
BIONUMERIK and GRELAN from and against any and all third party related claims,
damages or costs including attorney fees arising out of the failure by KI PHARMA
to distribute the Venture Products manufactured by BIONUMERIK or GRELAN in
accordance with applicable legal and regulatory requirements, the negligence of
KI PHARMA with respect to the Venture Products, or the non-compliance by KI
PHARMA with applicable laws and regulations in the Territory.


                                       28
<PAGE>   34



         18. DURATION AND TERMINATION OF AGREEMENT.

               18.1 Duration.

                  18.1.1(a) Unless otherwise terminated as set forth below, this
Agreement shall terminate upon the earlier to occur of (i) such time following
commercialization of the Venture Products, that Venture Products are no longer
being sold and/or distributed by KI PHARMA or its Sublicensees in the Territory
and (ii) 25 years after the effective date hereof.

                  18.1.1(b) This Agreement shall also immediately terminate if
the Effective Date does not occur within three months after the date of this
Agreement. In the event of termination pursuant to this Section 18.1.1(b), the
obligations and rights of the parties under this Agreement shall terminate,
except that the confidentiality obligations under Section 13 shall survive and
continue, and the rights and obligations under Section 17 and Section 22.12
shall survive and continue.

               18.2 Termination.

                  18.2.1. The parties hereto shall be able to terminate this
Agreement in the following events: (a) If a party to this Agreement shall
materially breach, materially default or otherwise materially fail to perform
under the terms of this Agreement or the Operating Agreement or any material
representation or warranty made by such party herein proves to have been
incorrect or misleading in any material respect when made, the other party or
parties may terminate this Agreement by giving 60 days advance written notice,
unless the breach, default or failure is cured within such notice period.

                          (b) If GRELAN or BIONUMERIK shall become bankrupt or
insolvent or any proceeding is commenced to place its business in the hands of a
receiver, assignee or trustee in bankruptcy, or any proceeding is commenced for
company reorganization (kaisha kosei), arrangement (seiri), civil rehabilitation
(minjisaisei), dissolution (kaisan) and liquidation (seisan), whether
voluntarily or otherwise, and such proceedings are not dismissed within ninety
(90) days of the commencement of any such proceeding, then the party that is not
bankrupt, insolvent or subject to such proceeding may terminate this Agreement
upon 30 days advance written notice.


                                       29
<PAGE>   35
                   (c) If, following the Effective Date, KI PHARMA is dissolved,
either GRELAN or BIONUMERIK may terminate this Agreement upon 30 days advance
written notice.

                   (d) If a third party Competitor (defined below) acquires a
Controlling Interest (defined below) in GRELAN, then BIONUMERIK may terminate
this Agreement by giving 60 days advance written notice.

                   (e) If a third party Competitor (defined below) acquires a
Controlling Interest (defined below) in BIONUMERIK, then GRELAN may terminate
this Agreement by giving 60 days advance written notice.

                   (f) For purposes hereof, "Competitor" shall mean a [**].

                   (g) For purposes hereof, "Controlling Interest" shall mean
(a) the ownership, whether directly or indirectly, of a majority of the voting
stock or equity interests, or substantially all of the assets or business of a
party, or (b) the ability, whether directly or indirectly, to appoint a majority
of the directors or other governing body of a party.

               18.3. Effect of Expiration or Termination. Termination is not the
sole remedy under this Agreement and termination of this Agreement for any
reason or the expiration of this Agreement shall not affect obligations or
rights of any party incurred or accrued prior to such termination or expiration.
The termination of this Agreement shall not affect the right of any party to
recover damages from any breach of this Agreement.






[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.


                                       30

<PAGE>   36



                  18.3.1 In the event of the expiration of this Agreement
pursuant to Section 18.1.1(a), or in the event of a valid termination of this
Agreement by either GRELAN or BIONUMERIK pursuant to Section 18.2.1 (c) or by KI
PHARMA pursuant to Section 18.2.1(a), the obligations and rights of the parties
under this Agreement shall terminate, except that the confidentiality
obligations under Section 13 shall survive and continue, the ownership and the
rights granted under Section 6.2.2 with respect to the Data and Results
resulting or obtained prior to such expiration or termination shall survive and
continue, the perpetual rights granted under Section 11 with respect to the
Improvements and KI PHARMA's new intellectual property resulting or obtained
prior to the expiration or termination shall survive and continue, and the
rights and obligations under Section 17 and Section 22.12 shall survive and
continue.

                  18.3.2 In the event of a valid termination of this Agreement
by GRELAN pursuant to Section 18.2.1(a), Section 18.2.1(b), or Section
18.2.1(e), then notwithstanding any provisions contrary to this Section 18.3.2,
(i) all licenses granted hereunder (whether contingent or perpetual) to the
Venture Products GR, and to the Grelan Improvements, Grelan Patent Rights, and
Know-How provided by GRELAN shall terminate, (ii) all licenses granted hereunder
(whether contingent or perpetual) to the Venture Products BN, and to the
BioNumerik Improvements, BioNumerik Patent Rights, and Know-How provided by
BIONUMERIK shall survive and continue without being affected, except that any
such licenses which are stated to be exclusive shall become non-exclusive after
such termination and the amounts of Upfront Payment and Royalties payable by KI
PHARMA for such products shall be reasonably adjusted as may be agreed to by the
parties hereto in good faith, and (iii) all rights, title and interest in the
Venture Products GR shall revert to GRELAN. For the avoidance of doubt, GRELAN
and BIONUMERIK shall retain the right to use the Data and Results as provided in
Section 6.2.2.

                  18.3.3. In the event of a valid termination of this Agreement
by BIONUMERIK pursuant to Section 18.2.1(a), Section 18.2.1(b), or Section
18.2.1(d), then notwithstanding any provisions contrary to this Section 18.3.3,
(i) all licenses granted hereunder (whether contingent or perpetual) to the
Venture Products BN, and to the BioNumerik Improvements, BioNumerik Patent
Rights, and Know-How provided by BIONUMERIK shall terminate, (ii) all licenses
granted hereunder (whether contingent or perpetual) to the Venture Products GR,
and to the Grelan Improvements, Grelan Patent Rights, and Know-How provided by
GRELAN shall survive and continue without being affected, except that any such
licenses which are stated to be exclusive shall become non-exclusive after such
termination and the amounts of Up-front Payment and Royalties payable by KI
PHARMA for such products shall be reasonably adjusted as may be agreed to by the
parties hereto in good faith, and (iii) all rights, title and interest in the


                                       31
<PAGE>   37

Venture Products BN shall revert to BIONUMERIK. For the avoidance of doubt,
BIONUMERIK and GRELAN shall retain the right to use the Data and Results as
provided in Section 6.2.2.

         19. BIONUMERIK REPRESENTATIONS & WARRANTIES.

               19.1 Due Organization and Authority. BIONUMERIK represents and
warrants: (i) that it is a corporation duly organized, validly existing and in
good standing under the laws of the State of Texas and has the corporate power
and authority to execute, deliver and carry out the terms and provisions of this
Agreement; (ii) that the execution, delivery and performance of this Agreement
by BIONUMERIK shall not require the consent of any third party (other than any
shareholder consents to be obtained prior to the Effective Date), and shall not
cause a breach or violation under any fiduciary, contractual, statutory or
judicial obligation or restraint to which BIONUMERIK is subject or bound; (iii)
that the person executing this Agreement on behalf of BIONUMERIK is duly
authorized to do so to bind the corporation, and (iv) that attached hereto as
Attachment F are audited Financial Statements of BIONUMERIK at and for the year
ended March 31, 2000, which Financial Statements are true and correct in all
material respects.

               19.2 Safety of Product(s). BIONUMERIK represents and warrants
that it has not received any notification of, and has no knowledge that there is
now pending or that there have been any United States judicial or administrative
orders to ban the development or use of any Venture Products BN and that
BIONUMERIK has no knowledge of any adverse reactions or test results encountered
or discovered regarding the use of any Venture Products BN which would render
such products unsuitable or unsafe for the purpose contemplated by this
Agreement, that have not been disclosed to GRELAN.

                19.3 No Pending Action Against BioNumerik. BIONUMERIK represents
and warrants that to its knowledge there is no action or proceeding pending
against BIONUMERIK relating to the Venture Products BN, and to its knowledge
there is no basis for or threat of any action or proceeding relating to the
Venture Products BN, which might result in a material adverse change in the
business or financial condition of BIONUMERIK which could adversely affect the
rights of GRELAN and KI PHARMA under this Agreement or the development of the
Venture Products.

                                       32

<PAGE>   38



         20. GRELAN REPRESENTATIONS AND WARRANTIES.

               20.1 Due Organization and Authority. GRELAN represents and
warrants: (i) that it is a corporation duly organized, validly existing and in
good standing under the laws of Japan and has the corporate power and authority
to execute, deliver and carry out the terms and provisions of this Agreement;
(ii) that the execution, delivery and performance of this Agreement by GR-ELAN
shall not require the consent of any third party and shall not cause a breach or
violation under any fiduciary, contractual, statutory or judicial obligation or
restraint to which GRELAN is subject or bound; and (iii) that the person
executing this Agreement on behalf of GRELAN is duly authorized to do so to bind
GRELAN.

               20.2 Safety of Product(s). GRELAN represents and warrants that it
has not received any notification of, and has no knowledge that there is now
pending or that there have been any Japan judicial or administrative orders to
ban the development or use of any Venture Products GR and that GRELAN has no
knowledge of any adverse reactions or test results encountered or discovered
regarding the use of any Venture Products GR which would render such products
unsuitable or unsafe for the purpose contemplated by this Agreement, which have
not been disclosed to BIONUMERIK.

               20.3 No Pending Action Against Grelan. GRELAN represents and
warrants that to its knowledge there is no action or proceeding pending against
GRELAN relating to the Venture Products GR, and to its knowledge there is no
basis for or threat of any action or proceeding relating to the Venture Products
GR, which might result in a material adverse change in the business or financial
condition of GRELAN which could adversely affect the rights of BIONUMERIK or KI
PHARMA under this Agreement or the development of the Venture Products.


         21. ASSIGNMENTS.

               21.1 Assignment Restrictions. Subject to Sections 21.2 and 21.3
below and excluding the sublicense rights expressly granted herein, no party
shall have the right to assign or delegate this Agreement, or any of its rights
or obligations under this Agreement without the express written consent of the
other parties, such consent not to be unreasonably withheld, and said assignment
or delegation without such consent shall be null and void for all purposes.


                                       33
<PAGE>   39


               21.2 Sale of Business. BIONUMERIK or GRELAN may assign its entire
interest in this Agreement to a third party other than a Competitor; provided
that (i) such assignment is part of the sale of all or substantially all of the
assignor's business related to the Venture Products; (ii) the ownership in all
Know-How, Patent Rights, Improvements and Trademarks of the assignor and all
interest of the assignor in KI PHARMA are assigned to such third party
simultaneously and are subject to any additional obligations contained in the
Operating Agreement; (iii) notice of any contemplated assignment is given to the
other party not less than 60 days prior to the effectiveness thereof; (iv)
following receipt of such notice, the assignor, if requested by the other party
and such assignment is contemplated to be made to a Competitor of the other
party, negotiates in good faith with the other party for a period of 40 days
with a view to finding a mutually satisfactory solution; and (v) the assignor
delivers to the other party a copy of the instrument, duly executed by the
parties thereto, effecting such assignment and affirming a complete assumption
by the assignee of the obligations of the assignor hereunder and a recognition
of the rights of the other party.

               21.3 Assignment to Affiliates. This Agreement and the rights and
obligations hereunder shall be assignable, in whole or in part, by BIONUMERIK,
without consent of GRELAN or KI PHARMA, to one or more Affiliates that is not a
Competitor of GRELAN or KI PHARMA and who shall affirm to GRELAN and KI PHARMA a
complete assumption of the obligations assigned; provided that BIONUMERIK shall
guarantee the performance by such Affiliates) of such obligations. This
Agreement and the rights and obligations hereunder shall be assignable, in whole
or in part, by GRELAN, without consent of BIONUMERIK or KI PHARMA, to one or
more Affiliates that is not a Competitor of BIONUMERIK or KI PHARMA and who
shall affirm to BIONUMERIK and KI PHARMA a complete assumption of the
obligations assigned; provided that GRELAN shall guarantee the performance by
such Affiliates) of such obligations.


         22. MISCELLANEOUS.

               22.1 Regulatory Communications. Each party agrees to notify the
other parties immediately by telephone (with prompt written follow-up in
English) of any inquiry, contact or communication received from any governmental
regulatory agency or other official body which materially and adversely relates
to or impacts upon the Venture Products or any component or ingredient thereof,
and will promptly furnish the other parties with copies of all written
communications relating thereto sent to or received from said regulatory agency.



                                       34
<PAGE>   40

               22.2 Adverse Events. Each party shall promptly inform the other
parties in writing of any material side effects or adverse events, conditions or
reactions encountered by or reported to them in connection with the Venture
Products which could in any significant way render any of the Venture Products
or any of the components thereof unsafe or unfit.

               22.3 Liability Insurance. KI PHARMA will maintain liability
insurance in amounts that are appropriate to protect against liabilities arising
in connection with the Venture Products in the Territory. GRELAN shall be
responsible for reimbursing KI PHARMA or otherwise bearing the cost of such
insurance with respect to each Venture Product until the time that such product
receives marketing approval in the Territory. After such time, the cost of such
insurance for an approved product in the Territory shall be paid 50% by GRELAN
and 50% by BIONUMERIK.

               22.4 Litigation. KI PHARMA will bear the costs of all non-patent
litigation relating to KI PHARMA and the Venture Products. GRELAN and BIONUMERIK
will each be responsible for reimbursing KI PHARMA or otherwise bearing the cost
of 50% of such litigation costs. KI PHARMA will advise BIONUMERIK with respect
to litigation strategies and operations in the Territory.

               22.5 Auditors. The auditors of KI PHARMA will be Ernst & Young or
another internationally recognized accounting firm approved by KI PHARMA, GRELAN
and BIONUMERIK. The audit report of the auditors will be in English. Each of
GRELAN and BIONUMERIK may select an additional accounting or auditing firm to
review the books and records of KI PHARMA, and all associated costs for such
additional firm will be paid by the party selecting it.

               22.6 Marketing Analysis and Reports. KI PHARMA and/or GRELAN
shall provide such reports and analyses as BIONUMERIK may reasonably request
containing English translations describing the market for and performance of the
Venture Products in the Territory, the market position and promotion of the
Venture Products in the Territory, competitive product information including
pricing and promotional information, and physician and consumer acceptance of
the Venture Products developed or obtained by KI PHARMA and/or GRELAN which
could affect the Venture Products in the Territory or generally. To assist in
the distribution of Venture Products in the Territory, KI PHARMA and/or GRELAN
shall regularly provide BIONUMERIK with information and data which will enable
BIONUMERIK to have a complete understanding of the general and specific markets
relating to the sale of Venture Products in the Territory.




                                       35
<PAGE>   41


               22.7 Notice / Reports. Any reports, notices or other
communications required or permitted to be given by any party hereto will be
given in writing by personal delivery, courier service or facsimile, or by
registered or certified air mail, postage prepaid, return receipt requested,
addressed to each respective party at the address shown below.

                           If to BIONUMERIK:

                           BioNumerik Pharmaceuticals, Inc.
                           8122 Datapoint Drive, Suite 1250
                           San Antonio, Texas 78229
                           Attn: Frederick H. Hausheer, M.D.
                           Facsimile No.: (210) 614-0643

                           If to GRELAN:

                           Grelan Pharmaceutical Co., Ltd.
                           Ogura Bldg. 5F
                           Nihonbashi Kobunacho 6-6
                           Chuo-ku, Tokyo 103-0024
                           Japan
                           Attn: Hashime Kanazawa, Ph.D.
                           Facsimile No. (81) 3-3281-5980

or to such other address as any party may indicate by proper notice to the other
parties in the same manner as provided herein; provided, however, that the
notices and opinions referred to in or required under Sections 10 and 18 shall
be given by personal delivery, courier service or registered or certified
airmail as mentioned above. All notices are deemed effective on the date of
receipt or, if delivery is not accepted, five (5) days after placement with the
addressee, an overnight courier service or a post office, as applicable.

               22.8 Severability. Should any provision of this Agreement be held
to be invalid, unenforceable, or against public policy, the remaining provisions
hereof shall not be affected thereby. In such event, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the parties as closely as possible with respect to those provisions
which were held to be invalid, unenforceable or against public policy.

               22.9 Counterparts. This Agreement may be executed in several
counterparts, each of which will be an original, but all of which, when taken
together, will constitute one and the same instrument.



                                       36
<PAGE>   42


                22.10 Warranty Disclaimer. EXCEPT AS EXPRESSLY PROVIDED IN
SECTIONS 19 AND 20, NEITHER BIONUMERIK NOR GRELAN MAKES ANY WARRANTY WITH
RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF
THIS AGREEMENT AND EACH OF BIONUMERIK AND GRELAN HEREBY DISCLAIMS WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH
RESPECT TO ANY AND ALL OF THE FOREGOING. THE PARTIES UNDERSTAND AND AGREE THAT
DEVELOPMENT AND COMMERCIALIZATION OF THE VENTURE PRODUCTS WILL INVOLVE APPROVAL
BY REGULATORY AUTHORITIES AND THAT NO PARTY IS GUARANTEEING THE SAFETY,
EFFICACY, MANUFACTURE OR REGULATORY APPROVAL OF ANY VENTURE PRODUCTS.


               22.11 Force Majeure.

                     22.11.1. Except for the payment of money, no failure or
omission by the parties hereto in the performance of any obligation of this
Agreement shall be deemed a breach of this Agreement nor create any liability,
if the same arises as a result of force majeure, i.e., any cause or causes
beyond the control of the parties, including, but not limited to the following,
which for the purposes of this Agreement, shall be regarded as beyond the
control of the party in question: acts of God; acts, omissions, rules,
regulations, or orders of any governmental authority or any officer,
department, agency or instrumentality thereof; fire; storm; flood; earthquake;
accident; acts of the public enemy; war; rebellion; insurrection; riot;
invasion; strikes, lockouts or shortages of raw materials or other supplies.

                     22.11.2. In the event of such cause intervening, such
excuse of performance shall be only to the extent that such non-performance is
beyond the reasonable control of the party bound by such covenant or
obligation; and the party so affected shall use its best efforts to eliminate
or cure or overcome any of such causes and to resume performance of its
covenants and obligations with all possible speed.

               22.12. Arbitration. All disputes, controversies or differences
which may arise among the parties, out of or in relation to or in connection
with this Agreement or the Operating Agreement, or the breach thereof, shall be
finally settled by arbitration, by the American Arbitration Association in
Honolulu, Hawaii, U.S.A., by a panel of three (3) arbitrators in accordance
with the then current American Arbitration Association International
Arbitration Rules, provided that the arbitrators will first render a
preliminary



                                       37
<PAGE>   43



decision setting forth their grounds for decision and providing at least thirty
(30) days for each of the parties to respond. The parties hereto expressly waive
any right to appeal such decision or to challenge the decision in any court.
Judgment thereof may be entered in any court of competent jurisdiction in the
United States or Japan. This clause shall not be used to prohibit the right of
any party to seek injunctive relief in appropriate circumstances.

               22.13 Export Controls. The parties agree to abide by the United
States and Japanese laws and regulations governing exports of the Venture
Products or any other technology developed or disclosed as a result of this
Agreement. The parties acknowledge that any performance under this Agreement is
subject to any restrictions which may be imposed by the United States and
Japanese laws and regulations governing exports. Each party agrees to provide
the other parties with any assistance, including written assurances, which may
be required by a competent governmental authority and by applicable laws and
regulation as a precondition for any disclosure of technology by the other
parties under the terms of this Agreement. In addition, the parties hereto agree
to take all actions as may reasonably be required to assure compliance with all
applicable requirements of the U.S. Foreign Corrupt Practices Act.

               22.14 Construction / Jurisdiction / Official Language. This
Agreement shall be construed in accordance with the laws of the State of Texas,
U.S.A. Subject to the arbitration provisions contained in Section 22.12, each
party hereto hereby irrevocably consents and submits to the jurisdiction of the
Courts of the State of Texas and of the United States of America for all
purposes in connection with any proceeding which arises out of or relates to
this Agreement. English shall be the official language of this Agreement and any
related agreement provided for hereunder and all communications between the
parties hereto shall be conducted in that language. Each party recognizes that
the parties hereto grant no licenses, by implication or otherwise, except for
the licenses expressly set forth in this Agreement. GRELAN agrees to promptly
provide BIONUMERIK with written English translations of (a) all material
reports, financial statements, and documents relating to the Venture Products or
this Agreement that are in Japanese and (b) other documents that are in Japanese
and relate to the Venture Products or this Agreement as may be reasonably
requested by BIONUMERIK.

               23. ENTIRE AGREEMENT. This Agreement comprises the entire
understanding and Agreement of the parties hereto with respect to the specific
subject matter of this Agreement, and supersedes all prior agreements or
understandings, written or oral, between the parties hereto with respect to the
specific subject matter of this Agreement. In addition, and except as otherwise
expressly provided




                                       38
<PAGE>   44

herein, those obligations under the existing confidentiality agreements,
materials transfer agreements, stock purchase agreements, and related agreements
between and among BIONUMERIK and GRELAN, and in certain cases certain third
parties, shall continue in full force and effect in accordance with their terms.
This Agreement may not be amended except by a written instrument signed by
GRELAN and BIONUMERIK.

               24. CAPTIONS. The captions used in this Agreement are for
purposes of clarification only and are not meant to be construed as part of this
Agreement.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first written above.

<TABLE>
<S>                                                    <C>
GRELAN PHARMACEUTICAL CO., LTD.                        BIONUMERIK PHARMACEUTICALS, INC.


By:                                                    By:
   ---------------------------------------                ---------------------------------------
       Hashime Kanazawa, Ph.D.                                Frederick H. Hausheer, M.D.
       C.O.O. & Vice President - Director                     Chairman & Chief Executive Officer

Date:  30th Aug. 2000                                  Date:  30th Aug. 2000
</TABLE>




                                       39
<PAGE>   45



                                 ATTACHMENT A-1

         [**]









[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.




                                       40
<PAGE>   46



                                 ATTACHMENT A-2

         [**]









[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       41
<PAGE>   47



                                 ATTACHMENT A-3

         [**]





[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.




                                       42
<PAGE>   48



                                 ATTACHMENT A-4

         [**]








[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.




                                       43

<PAGE>   49



                                 ATTACHMENT A-5

         [**]







[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.




                                       44
<PAGE>   50

                                                                    CONFIDENTIAL


                                 ATTACHMENT B-1


         [**]









[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       45
<PAGE>   51



                                                                    CONFIDENTIAL


                                 ATTACHMENT B-2


         [**]






[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.





                                       46
<PAGE>   52
                                  ATTACHMENT C


                                                                    CONFIDENTIAL


         [**]






[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       47
<PAGE>   53


                                  ATTACHMENT D

         [**]








[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.



                                       48
<PAGE>   54


                                  ATTACHMENT E





         [**]





[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.




                                       49
<PAGE>   55



                                                               CONFIDENTIAL
                                                                 (Grelan's part)




                                  ATTACHMENT E

         [**]






[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.


                                       50
<PAGE>   56
                                 ATTACHMENT F



                           [INTENTIONALLY OMITTED]























                                      51
<PAGE>   57
                                 ATTACHMENT G


                           [INTENTIONALLY OMITTED]






























                                      52